To evaluate the efficacy and safety of mivocabtagene autoleucel in adults with antibody-positive stiff person syndrome (SPS) who had responded inadequately to prior immunomodulatory treatment.
Approach:
Design: Multicenter, open-label phase 2 KYSA-8 trial enrolling 27 adults; 26 received one infusion after low-dose lymphodepleting chemotherapy.
Assessment: The primary efficacy endpoint was change in the timed 25-foot walk test at week 16. Secondary outcomes included stiffness, hypersensitivity, disability, and mobility; safety and biomarkers were also assessed.
Key Findings:
At week 16, the median improvement in timed 25-foot walk performance was 45.6%; more than 80% of participants had clinically meaningful improvement in walking speed.
Eight of 12 participants who initially used walking aids no longer required them.
Improvements were reported across secondary measures. All 26 treated participants remained off SPS-directed immunomodulatory or immunosuppressive therapy at latest follow-up, which had a median duration of 6.5 months.
Peripheral B-cell depletion was observed by day five. Among participants with elevated GAD65 autoantibodies, median antibody levels fell 56% by week 16.
Cytokine release syndrome occurred in 92.3% of participants, all at grade 1 or 2; three had grade 1 neurotoxicity, and five (19.2%) had grade 3 or 4 neutropenia. No deaths or adverse-event-related discontinuations were reported.
Interpretation:
The trial authors reported improvements in mobility and other SPS measures after a single infusion. They stated that long-term follow-up to establish the durability of benefits is in progress.
Limitations:
The trial was open-label and included 26 treated participants.
Latest follow-up had a median duration of 6.5 months; durability of benefit remains under investigation.